Akorn, Inc. (NASDAQ:AKRX)

CAPS Rating: 3 out of 5

The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.


Player Avatar HealthcareGuy (99.50) Submitted: 12/29/2010 4:44:02 PM : Outperform Start Price: $5.39 AKRX Score: +513.13

Akorn, is a generic pharma company that has been remade by successful healthcare turnaround investor John Kapoor (Chariman of the Board). The major catalyst for this name, will be FDA approval of AKRX’s generic version of Vancocin (first to file, been in FDA limbo for many years). Even branded Vanco manufacturer, Viropharma, has hinted that they believe 2011 will be the year they finally lose their vanco monopoly, which will probably send AKRX to the $12 range (assuming they receive a 6 month exclusivity)

Member Avatar HealthcareGuy (99.50) Submitted: 5/24/2011 10:37:28 AM
Recs: 1

Generic Vanco trade- Long AKRX, Short VPHM

Featured Broker Partners